The Psoriasis Drugs Market report segments the industry into By Type Of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies), By Mechanism Of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, Other Mechanisms Of Action), By Route Of Administration (Oral, Parenteral, Topical), and Geography (North America, Europe, Asia-Pacific, Middle-East And Africa, South America).

This statistic shows the psoriasis drugs market in the United States from 2022 to 2030. Psoriasis is a chronic and common disease that is characteristic of red, scaly patches that form on the skin all over the body. The disease is mediated by the immune system. The U.S. psoriasis market is expected to be worth around 18 billion U.S. dollars by 2030.

The psoriasis drugs market size was valued at USD 21.6 billion in 2024 and is likely to cross USD 76.3 billion by 2037, registering more than 11.1% CAGR during the forecast period, i.e., 2025-2037. North America industry is anticipated to capture a significant share of 38.9% by 2037 due to improved access to healthcare in the region.

The Psoriasis Drugs Market size is expected to reach a valuation of USD 52.34 billion in 2033 growing at a CAGR of 11.50%. The Psoriasis Drugs market research report classifies market by share, trend, demand, forecast and based on segmentation.

Psoriasis Drugs Market is expected to reach USD 37.07 Billion by 2030, is projected to grow at a CAGR 8.90% during the forecast period

Psoriasis Drugs Market Outlook

The global psoriasis drugs market size is anticipated to see an impressive growth trajectory over the forecast period from 2024 to 2032, with a compound annual growth rate (CAGR) of approximately 9.5%. In 2023, the market was valued at approximately USD 15 billion, and is expected to reach around USD 35 billion by 2032. The growth of this market is driven by factors such as increased prevalence of psoriasis, advancements in biologic therapies, and rising awareness among patients and healthcare providers. Furthermore, the continuous development and approval of novel drugs that offer enhanced efficacy and safety profiles are fueling market expansion. An increasing number of clinical trials and research activities aimed at discovering new therapeutic avenues also contribute to the growth dynamics of this market.

One of the primary growth factors of the psoriasis drugs market is the increasing prevalence of psoriasis worldwide. Psoriasis affects approximately 2-3% of the world's population, translating to millions of individuals who require effective treatment options. The chronic nature of the disease and its impact on quality of life necessitate the development of more effective and longer-lasting therapeutic interventions. This demand has spurred significant research and development activities, resulting in the introduction of new biologic therapies that target specific pathways involved in psoriasis pathogenesis. As more patients and healthcare professionals recognize the benefits of these advanced therapies, the demand for psoriasis drugs continues to rise.

Advancements in biologic therapies represent another significant growth driver for the psoriasis drugs market. Biologics, which are derived from living cells, have revolutionized the treatment landscape for moderate to severe psoriasis. These drugs target specific components of the immune system, providing a more targeted approach compared to traditional systemic treatments. The introduction of biologics such as interleukin inhibitors and tumor necrosis factor-alpha inhibitors has significantly improved patient outcomes, offering sustained psoriasis clearance and improved quality of life. Ongoing research and clinical trials continue to enhance the efficacy and safety profiles of biologics, thereby expanding their adoption among patients and clinicians alike.

Rising awareness among patients and healthcare providers about psoriasis and its available treatment options is another catalyst for market growth. Educational initiatives and awareness campaigns conducted by healthcare organizations and pharmaceutical companies are playing a pivotal role in enhancing the understanding of psoriasis and its management. As patients become more informed about the chronic nature of the disease and the importance of adhering to prescribed treatments, they are more likely to seek medical advice and adhere to therapeutic regimens. This trend is further supported by the increased availability of resources and information through online platforms, empowering patients to make informed decisions about their healthcare.

Drug Type Analysis

The psoriasis drugs market is segmented into different drug types, including biologics, small molecules, systemic agents, and topical agents, among which biologics hold a significant share. Biologics have emerged as the preferred choice for treating moderate to severe psoriasis due to their targeted mechanism of action and superior efficacy compared to conventional therapies. These advanced medications inhibit specific molecules involved in the immune response, thereby reducing inflammation and skin cell proliferation. The rise of biosimilars, which are similar to existing biologic drugs, is also contributing to the growth of this segment by offering cost-effective alternatives for patients and healthcare systems.

Small molecules, although not as dominant as biologics, hold a crucial role in the treatment landscape, especially for patients with mild to moderate psoriasis. These compounds, which can be administered orally, work by modulating immune pathways involved in the disease process. Although traditionally used systemic agents have faced challenges due to side effects and limited efficacy, newer small molecules are being developed with improved safety profiles and enhanced therapeutic benefits. The introduction of these next-generation small molecules is expected to drive growth in this segment, providing additional treatment options for patients who may not respond adequately to biologics or prefer alternative administration routes.

Systemic agents continue

Worldwide sales of psoriasis drugs are expected to reach US$ 14.08 billion in 2024 and further increase at a CAGR of 6.9% to climb to US$ 27.57 billion by 2034-end.

Report Attributes	Details
Psoriasis Drug Market Size (2024E)	US$ 14.08 Billion
Forecasted Market Value (2034F)	US$ 27.57 Billion
Global Market Growth Rate (2024 to 2034)	6.9% CAGR
Canada Market Growth Rate (2024 to 2034)	8.2% CAGR
Brazil Market Value (2034F)	US$ 1.01 Billion
North America Market Share (2024E)	29.9%
Latin America Market Share (2034F)	10.4%
Key Companies Profiled	Amgen Inc. Eli Lilly and Company Novartis Johnson & Johnson AstraZeneca Plc LEO Pharma A/S Biogen Inc. Sun Pharmaceutical Industries Pfizer Inc. Celgene Corporation Boehringer Ingelheim Merck

Country-wise Evaluation

Attribute	United States
Market Value (2024E)	US$ 3.52 Billion
Growth Rate (2024 to 2034)	7.7% CAGR
Projected Value (2034F)	US$ 7.41 Billion

Attribute	Brazil
Market Value (2024E)	US$ 596 Million
Growth Rate (2024 to 2034)	5.4% CAGR
Projected Value (2034F)	US$ 1.01 Billion

Category-wise Insights

Attribute	Corticosteroids
Segment Value (2024E)	US$ 4.91 Billion
Growth Rate (2024 to 2034)	7.2% CAGR
Projected Value (2034F)	US$ 9.88 Billion

Attribute	Guttate Psoriasis
Segment Value (2024E)	US$ 400 Million
Growth Rate (2024 to 2034)	11.1% CAGR
Projected Value (2034F)	US$ 1.14 Billion

Global Psoriasis Drugs Market was valued at USD 21.06 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.57%

Pages	183
Market Size	2024: USD 21.06 Billion
Forecast Market Size	2030: USD 30.60 Billion
CAGR	2025-2030: 6.57%
Fastest Growing Segment	Oral
Largest Market	North America
Key Players	1. Glanbia Plc 2. Pfizer Inc. 3. Bayer AG 4. Amway Corp. 5. GlaxoSmithKline plc. 6. Good Health New Zealand 7. The Nature's Bounty Co. 8. NOW Foods 9. Abbott 10. Herbalife Nutrition

Psoriasis Drug Market expected to rise from USD 22.63 billion in 2025 to USD 56.96 billion by 2034, at a CAGR of 10.8% during the forecast period.

The size of the Global Psoriasis Drugs Market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 9.89% during the forecast period. Psoriasis is an autoimmune chronic disease with zones of reddened, thick, scaly skin. According to a report, this disease arises out of an exaggerated immune reaction in which the genetic makeup provokes a faster acceleration in the growth of skin cells. Despite the unknown cause, it is thought that genetics and environmental factors trigger this disease. Pain related to psoriasis, psychological problems, and even social embarrassment can dramatically affect the quality of life. The drugs for psoriasis focus on symptom control for the condition and generally enhance the quality of life in the patient. These drugs work by interfering with selected aspects of the immune dysfunction. Treatment options depend on the severity of the disorder; they can be topical creams and ointments, light therapy, or systemic drugs. Topical treatment, which includes corticosteroids and vitamin D analogs, is the most common for mild conditions. Light therapy, for example ultraviolet A and ultraviolet B, can reduce inflammation and may clear the skin lesion. Systemic drugs are biologics and non-biologics. These are, by and large, reserved for patients who have moderate to severe psoriasis. Biologics represent targeted therapies aimed at interrupting certain proteins that are perpetuating parts of the immune response; an example of biologics is methotrexate, and another non-biologic is cyclosporine. Recent developments include: In July 2022, Arcutis Biotherapeutics, Inc. received the United States Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older., In May 2022, Dermavant Sciences received United States Food and Drug Administration (FDA) approval for VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults. This approval makes VTAMA cream the first and only FDA-approved steroid-free topical medication in its class.. Key drivers for this market are: Increasing Disease Burden and Demand for Psoriasis Medicines in Emerging Economies, Increasing Use of Combination Therapies; Increase in Psoriasis Research and Pipeline Drugs. Potential restraints include: Adverse Side Effects of Existing Medications, High Cost of Psoriasis Treatments; Extensive Drug Development and Approval Process. Notable trends are: Interleukin Inhibitors Segment are Expected to Register a High CAGR Over the Forecast Period.

The global psoriasis drugs market is experiencing robust growth, driven by rising prevalence of psoriasis, an increasing awareness of available treatments, and the continuous development of innovative therapies. The market, valued at approximately $XX million in 2025 (assuming a logical extrapolation from the provided data and considering the 9.89% CAGR), is projected to expand significantly over the forecast period (2025-2033). This expansion is fueled by several key factors: the introduction of novel biologics and small molecule drugs offering improved efficacy and safety profiles, a shift towards earlier and more aggressive treatment strategies, and expanding access to healthcare in emerging economies. The market segmentation reveals strong performance across various treatment types, with biologics like TNF-alpha inhibitors maintaining a substantial share due to their established efficacy. However, the growing adoption of oral therapies and topical treatments is expected to drive market diversification in the coming years. The competitive landscape is characterized by the presence of major pharmaceutical companies constantly engaged in research and development, seeking to expand their product portfolios and solidify their market positions. Regional variations in market growth are expected, with North America and Europe continuing to hold significant shares, while the Asia-Pacific region shows high growth potential due to increasing disease prevalence and improved healthcare infrastructure. Despite the positive growth trajectory, certain factors could potentially restrain market expansion. High drug costs, particularly for biologic therapies, remain a significant barrier to access for many patients, impacting market penetration, especially in low- and middle-income countries. Additionally, the development of biosimilars and the emergence of generic medications may exert downward pressure on pricing and profitability for established players. Furthermore, the long-term safety profiles of certain drugs and the potential for adverse events need ongoing monitoring and management. Nevertheless, the overall outlook for the global psoriasis drugs market remains optimistic, driven by innovation, rising awareness, and expanding treatment access. Continued research into novel therapeutic targets and improved delivery mechanisms will likely shape future market dynamics. Recent developments include: In July 2022, Arcutis Biotherapeutics, Inc. received the United States Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older., In May 2022, Dermavant Sciences received United States Food and Drug Administration (FDA) approval for VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults. This approval makes VTAMA cream the first and only FDA-approved steroid-free topical medication in its class.. Key drivers for this market are: Increasing Disease Burden and Demand for Psoriasis Medicines in Emerging Economies, Increasing Use of Combination Therapies; Increase in Psoriasis Research and Pipeline Drugs. Potential restraints include: Increasing Disease Burden and Demand for Psoriasis Medicines in Emerging Economies, Increasing Use of Combination Therapies; Increase in Psoriasis Research and Pipeline Drugs. Notable trends are: Interleukin Inhibitors Segment are Expected to Register a High CAGR Over the Forecast Period.

Psoriasis Treatment Drugs Market Outlook

As of 2023, the global market size for psoriasis treatment drugs was valued at approximately USD 15.6 billion, with a forecasted growth to USD 27.3 billion by 2032, reflecting a robust CAGR of 6.5%. The substantial market growth can be attributed to increasing prevalence of psoriasis worldwide, advancements in biologic drugs, and a growing awareness about the disease and its treatment options.

One of the primary growth factors driving the psoriasis treatment drugs market is the rising prevalence of psoriasis globally. According to recent statistics, approximately 2-3% of the worldÂ’s population is affected by psoriasis, a chronic autoimmune condition characterized by inflamed, scaly patches on the skin. The growing number of cases has amplified the demand for effective and long-lasting treatment options, thereby propelling the market's expansion. Additionally, increased awareness campaigns and patient education initiatives by healthcare organizations have led to early diagnosis and treatment, further boosting the market.

Another significant factor contributing to market growth is the continuous innovation and development of biologic drugs. These advanced medications target specific parts of the immune system, thereby reducing inflammation and plaque formation more effectively than traditional treatments. The development of new biologics and biosimilars has opened new avenues for treatment, offering hope to patients who did not respond well to conventional therapies. With pharmaceutical companies intensively investing in R&D, the pipeline for new psoriasis drugs continues to expand, promising better management of the condition.

The increasing adoption of combination therapies is also contributing to market growth. Combination therapies, which often include a mix of topical treatments, phototherapy, and systemic medications, have shown better efficacy in managing moderate to severe psoriasis. This multi-faceted approach not only improves patient outcomes but also reduces the likelihood of adverse side effects associated with high doses of a single drug. As a result, healthcare providers are increasingly prescribing combination therapies, which has, in turn, driven demand for a variety of psoriasis treatment drugs.

Dermatology Biologics have emerged as a transformative force in the treatment of psoriasis, offering targeted therapies that address the underlying immune processes of the disease. These biologics are engineered to interfere with specific pathways in the immune system, providing relief from the chronic symptoms associated with psoriasis. Unlike traditional systemic treatments, dermatology biologics offer a more precise approach, minimizing the risk of widespread side effects. As research in this field continues to evolve, new biologics are being developed that promise even greater efficacy and safety. The introduction of these advanced therapies has not only improved patient outcomes but also expanded the arsenal of treatment options available to healthcare providers. With ongoing clinical trials and innovations, dermatology biologics are set to play an increasingly pivotal role in managing psoriasis and other dermatological conditions.

From a regional perspective, North America holds a significant share in the psoriasis treatment drugs market due to the high prevalence of the disease, well-established healthcare infrastructure, and the presence of major pharmaceutical companies. Europe follows closely, benefiting from strong healthcare systems and government support for medical research. The Asia Pacific region is expected to witness the highest CAGR during the forecast period, driven by a growing patient population, increased healthcare spending, and rising awareness about psoriasis and its treatments.

Drug Class Analysis

The psoriasis treatment drugs market is segmented into various drug classes, including TNF inhibitors, PDE4 inhibitors, interleukin inhibitors, corticosteroids, and others. Among these, TNF inhibitors have historically dominated the market due to their efficacy in reducing inflammation and controlling symptoms of psoriasis. TNF inhibitors work by blocking the tumor necrosis factor, a protein that plays a crucial role in the inflammatory process of psoriasis. Despite their effectiveness, these drugs are often associated with severe side effects, which have prompted the development of safer alternatives.

PDE4 inhibitors repres

Psoriasis Drugs Market Outlook

According to our latest research, the global psoriasis drugs market size reached USD 27.4 billion in 2024, driven by rising disease prevalence and increasing adoption of advanced biologics. The market is exhibiting a robust growth trajectory with a CAGR of 8.2% during the forecast period. By 2033, the psoriasis drugs market is projected to attain a value of USD 54.3 billion. This sustained expansion is attributed to continuous innovation in drug development, expanding patient awareness, and the growing accessibility of novel treatment options across both developed and emerging regions.

One of the primary growth factors propelling the psoriasis drugs market is the escalating prevalence of psoriasis globally. The World Health Organization estimates that psoriasis affects approximately 2-3% of the world’s population, translating to over 125 million people worldwide. This chronic, immune-mediated disease not only impacts the skin but is also linked with several comorbidities, such as psoriatic arthritis, cardiovascular disease, and metabolic syndrome. The rising burden of these associated conditions further amplifies the demand for effective psoriasis therapies. In addition, increasing awareness campaigns by governmental and non-governmental organizations are improving diagnosis rates and ensuring more patients seek medical intervention, which in turn boosts the uptake of psoriasis drugs.

Another significant driver for the psoriasis drugs market is the rapid advancement and adoption of biologic therapies. Biologics have revolutionized the management of moderate to severe psoriasis by targeting specific immune pathways, resulting in higher efficacy and improved safety profiles compared to conventional systemic therapies. The approval of new biologics, such as IL-17 and IL-23 inhibitors, has expanded the treatment landscape, offering patients more personalized and effective options. Pharmaceutical companies are heavily investing in research and development, leading to a strong pipeline of innovative molecules. The growing physician and patient preference for biologics, coupled with favorable reimbursement policies in many countries, is expected to further accelerate market growth over the coming years.

The expansion of healthcare infrastructure and increased access to psoriasis treatments in emerging markets also play a pivotal role in market growth. Countries in Asia Pacific and Latin America are witnessing improvements in healthcare delivery, increased healthcare spending, and greater availability of advanced drugs. These regions are experiencing a shift in treatment paradigms, with a gradual transition from traditional topical agents to systemic and biologic therapies. Additionally, the proliferation of online pharmacies and telemedicine platforms has facilitated easier access to prescription medications, particularly in remote and underserved areas. Consequently, the combination of enhanced healthcare access and rising disease awareness is expected to drive substantial growth in the psoriasis drugs market across these emerging economies.

From a regional perspective, North America continues to dominate the global psoriasis drugs market, accounting for the largest revenue share in 2024. This leadership is attributed to high disease prevalence, robust healthcare infrastructure, and rapid adoption of innovative therapies. Europe follows closely, supported by strong reimbursement frameworks and active research initiatives. Meanwhile, Asia Pacific is emerging as the fastest-growing region, with a projected CAGR exceeding 10% during the forecast period. The region's growth is underpinned by increasing healthcare investments, rising patient awareness, and expanding access to advanced treatments. Latin America and the Middle East & Africa are also witnessing steady growth, albeit from a smaller base, as healthcare systems in these regions continue to evolve and modernize.

Drug Class Analysis

The psoriasis drugs mar

Global Psoriasis market size is expected to reach $42.34 billion by 2029 at 9.4%, prevalence of psoriasis driving market growth

According to Cognitive Market Research, The Psoriasis Drugs Market will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031. North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031. The Europe region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and is projected to grow at a CAGR of XX% in the future. Asia Pacific accounted for a market share of over XX% of the global revenue with a USD XX million market size. Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. The Psoriasis Drugs Market held the highest market revenue share in 2024. Market Dynamics of the Psoriasis Drugs Market

Key Drivers for The Psoriasis Drugs Market

Growing prevalence of psoriasis to boost psoriasis drugs market growth.

The main driver that increased the demand for psoriasis drugs is the growing prevalence of patients suffering from psoriasis. Over 8 million Americans suffer from psoriasis, according to data released by the National Psoriasis Foundation in 2023. Additionally, in an effort to better inform patients on the management of psoriasis, the government and businesses involved in the industry are initiating a number of awareness campaigns. In addition, it is projected that the introduction of new medications to speed up the treatment of psoriasis will support market expansion in the years to come. For instance, in Nov 2020, Bristol Myers Squibb introduced Deucravacitinib (BMS-986165) in individuals with psoriatic arthritis was shown to be safe and effective in late-breaking Phase 2 data. It encourages patients who are wary of injectables to use them more effectively. Source:(https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Deucravacitinib-BMS-986165-Demonstrated-Superiority-to-Placebo-and-Otezla-apremilast-in-Pivotal-Phase-3-Psoriasis-Study/default.aspx) For instance, in June 2023, the American Academy of Dermatology, in collaboration with Boehringer Ingelheim International GmbH, launched innovative breakthrough project to develop educational resources with an aim to improve the evaluation, diagnosis, and treatment of patients suffering from Generalized Pustular Psoriasis (GPP). Source:(https://www.aad.org/news/aad-generalized-pustular-psoriasis-education-initiative#:~:text=(June%2022%2C%202023)%20%E2%80%93,resources%20to%20improve%20the%20evaluation%2C) Therefore, the growing incidence of patients suffering from psoriasis drives the market for psoriasis drugs.

An increase in R&D funding by private and public organizations propelled the market growth of psoriasis drug market. 

Increased research and development (R&D) funding from both private and public organizations has propelled growth in the psoriasis drug market. This surge in funding has enabled accelerated innovation in therapies aimed at managing and potentially curing psoriasis. With more resources allocated to R&D, pharmaceutical companies and research institutions can conduct extensive clinical trials, develop novel drug formulations, and explore combined drug therapy approaches tailored to psoriasis patients. Furthermore, enhanced funding supports the expansion of infrastructure for diagnosis, treatment, and patient care, fostering a more robust ecosystem for psoriasis management. Ultimately, these investments contribute to the discovery of more effective treatments and improved outcomes for individuals living with psoriasis disease.

For instance, in Nov 2020, Bristol Myers Squibb introduced Deucravacitinib (BMS-986165) in individuals with psoriatic arthritis was shown to be safe and effective in late-breaking Phase 2 data. It encourages patients who are wary of injectables to use them more effectively. Source:(https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Deucravacitinib-BMS-986165-Demonstrated-Superiority-to-Placebo-and-Otezla-apremilast-in-Pivota...

Check out Market Research Intellect's Psoriasis Treatment Drugs Market Report, valued at USD 27.5 billion in 2024, with a projected growth to USD 45.2 billion by 2033 at a CAGR of 7.5% (2026-2033).

Recent developments include: In May 2024, Innovent Biologics revealed the success of the Phase III trial of the use of IBI306 in treating psoriasis. In terms of efficacy, the study showed that the patients had better scores of psoriasis symptoms when compared to a placebo. Such data put forward IBI306 as a possible new treatment for patients with moderate to severe psoriasis. , In October 2023, UCB launched its drug, BIMZELX (bimekizumab), for treating adults with moderate to severe psoriasis. This approval is derived from clinical evaluations showing that BIMZELX reduces psoriasis significantly as compared to other medications. .

Vietnam Psoriasis Drugs Market is attributed to increasing demand for biologic therapies, rising awareness of psoriasis, and advancements in drug development.

India Psoriasis Drugs Market is attributed to increasing demand for biologic therapies, rising awareness of psoriasis, and advancements in drug development.

The Global Psoriasis Treatment Market is expected to grow at a rate of 8.5% by 2026. The growing prevalence of psoriasis, increased demand for psoriasis medicines in emerging economies, growing approval of new biologics drugs for psoriasis treatment, increased activity for psoriasis research, a strong pipeline of drugs, and increased usage of combined therapies for […]